Show simple item record

dc.contributor.advisorSutton, Chris W.
dc.contributor.advisorPatterson, Laurence H.
dc.contributor.authorShaheed, Sadr-ul*
dc.date.accessioned2018-02-01T14:44:25Z
dc.date.available2018-02-01T14:44:25Z
dc.date.issued2017
dc.identifier.urihttp://hdl.handle.net/10454/14785
dc.descriptionThe CD-ROM disc containing supplementary material is kept in the cardboard box in the Systems Office.en_US
dc.description.abstractThe heterogeneity of breast cancer (disease stage and phenotype) makes it challenging to differentiate between each subtype; luminal A, luminal B, HER2, basal-like and claudin-low, on the basis of a single gene or protein. Therefore, a collection of markers is required that can serve as a signature for diagnosing different types of breast cancer. New developments in proteomics have provided the opportunity to look at phenotype-specific breast cancer cell lines and stage-specific liquid biopsies (nipple aspirate fluid [NAF], plasma samples) to identify disease and phenotype specific signature. An 8-plex iTRAQ quantification strategy was employed to compare proteomic profiles of a range of breast cancer and ‘normal-like’ cell lines with primary breast epithelial cells. From this, 2467 proteins were identified on Orbitrap Fusion and Ultraflex II, of which 1430 were common. Matched pairs of NAF samples from four patients with different stages of breast cancer, were analysed by SCX-LC-MS and a total of 1990 unique gene products were identified. More than double the number of proteins previously published data, were detected in NAF, including 300 not detected in plasma. The NAF from the diseased patients have 138 potential phenotype biomarkers that were significantly changed compared to the healthy volunteer (7 for luminal A, 9 for luminal B, 11 for HER2, 14 for basal-like and 52 for claudin-low type). The average coefficient of variation for triplicate analyses by multiple reaction monitoring mass spectrometry (MRM-MS), was 9% in cell lines, 17 % in tissue biopsies, 22% in serum samples and 24% in NAF samples. Overall, the results provide a strong paradigm to develop a clinical assay based on proteomic changes in NAF samples for the early detection of breast cancer supplementary to established mammography programmes.en_US
dc.language.isoenen_US
dc.rights<a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="Creative Commons License" style="border-width:0" src="http://i.creativecommons.org/l/by-nc-nd/3.0/88x31.png" /></a><br />The University of Bradford theses are licenced under a <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Licence</a>.en_US
dc.subjectBreast cancer; Detection; Biomarkers; Proteomics; Bio-fluids; Nipple Aspirate Fluid; Luminal; Basal; Biopsies.en_US
dc.titleOncoproteomic applications for detection of breast cancer. Proteomic profiling of breast cancer models and biopsiesen_US
dc.type.qualificationleveldoctoralen_US
dc.publisher.institutionUniversity of Bradfordeng
dc.publisher.departmentFaculty of Life Sciencesen_US
dc.typeThesiseng
dc.type.qualificationnamePhDen_US
dc.date.awarded2017
dc.description.publicnotesThe supplementary material submitted with the thesis is not available online.en
refterms.dateFOA2018-07-28T02:51:51Z


Item file(s)

Thumbnail
Name:
Sadr-10014031 PhD thesis complete ...
Size:
12.48Mb
Format:
PDF
Description:
PhD Thesis

This item appears in the following Collection(s)

Show simple item record